Evidence map›Paper›PMID 33246450›Full record

ArticleBMC complementary medicine and therapies2020

Identification of the anti-breast cancer targets of triterpenoids in Liquidambaris Fructus and the hints for its traditional applications.

Ping Qian, Xiao-Ting Mu, Bing Su, Lu Gao, Dong-Fang Zhang

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Bioactivity of the Ethanol Extract of Clove (International journal of food science · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Betulin, a Newly Characterized Compound inMolecules (Basel, Switzerland) · 2021
    Article
  8. Integrated Strategy of UHPLC-Q-TOF-MS and Molecular Networking for Identification of Diterpenoids fromEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ping QianDepartment of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, China.
Xiao-Ting MuDepartment of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, China.
Bing SuDepartment of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, China.
Lu GaoDepartment of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, China.
Dong-Fang ZhangDepartment of Pharmacognosy, School of Pharmacy, China Medical University, Shenyang, 110122, China. dfzhang@cmu.edu.cn.
China Medical University · CN

Funding

National Natural Science Foundation of China 81703756Natural Science Foundation of Liaoning Province 20170541028
6 · The paper itself

Abstract

backgroundLiquidambaris Fructus is the infructescences of Liquidambar formosana Hance and it has been used to treat some breast disease in Traditional Chinese Medicine. In the previous study we found the anti-breast cancer effect of triterpenoid in Liquidambaris Fructus. This study is a further investigation of the triterpenoids in Liquidambaris Fructus and aims to identify their anti-breast cancer targets, meanwhile, to estimate the rationality of the traditional applications of Liquidambaris Fructus.

methodsTriterpenoids in Liquidambaris Fructus were isolated and their structures were identified by NMR spectrums. Potential targets of these triterpenoids were predicted using a reverse pharmacophore mapping strategy. Associations between these targets and the therapeutic targets of breast cancer were analyzed by constructing protein-protein interaction network, and targets played important roles in the network were identified using Molecular Complex Detection method. Binding affinity between the targets and triterpenoids was studied using molecular docking method. Gene ontology enrichment analysis was conducted to reveal the biological process and signaling pathways that the identified targets were involved in.

resultsThirteen triterpenoids were identified and 6 of them were the first time isolated from Liquidambaris Fructus. Predicted ADME properties revealed a good druggability of these triterpenoids. We identified 18 protein targets which were closely related to breast cancer progression, especially triple-negative, basal-like or advanced stage breast cancers. The triterpenoids could bind with these targets as their inhibitors: hydrophobic skeleton is a favorable factor for them to stabilize at binding site and polar C17- or C3- substituent was necessary for binding. GO enrichment analysis indicated that inhibition of protein tyrosine kinases autophosphorylation might be the primary mechanism for the anti-breast cancer effect of the triterpenoids, and ErbB4 and EGFR were the most relevant targets.

conclusionsThe study revealed that triterpenoids from Liquidambaris Fructus might exert anti-breast cancer effect by directly inhibit multiple protein targets and signaling pathways, especially ErbB4 and EGFR and related pathways. This study also brings up another hint that the traditional applications of Liquidambaris Fructus on hypogalactia should be reassessed systematically because it might suppress rather than promote lactation by inhibiting the activity of ErbB4.

Indexed as

Molecular Docking SimulationProtein Interaction MapsAntineoplastic AgentsApoptosisHumansLiquidambarMedicine, Chinese TraditionalMolecular StructureTriterpenesAntineoplastic AgentsTriterpenesBreast cancerEGFRErbB4Liquidambaris FructusMolecular dockingNetwork pharmacologyTriterpenoids

Identifiers

PMID33246450
PMCPMC7694930
OpenAlexW3107770127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.